Repair and connective tissue
Conceptual educational illustration of SR-0379 in a glass vial, labelled MOLECULE PROFILE.

View full illustrationSave SR-0379

MOLECULE PROFILE

SR-0379

Peptide or peptide-related

Functional peptide investigated in wound repair.

Sources checked · October 16, 2026

Published for review · Scientific, medical, translation and citation review pending. Reported uses are not authorized indications. Frequency reflects mentions in supplied sources, not sales or global clinical prevalence.

Identity and synonyms

Identity follows the supplied name and synonyms; no additional identity description is supplied.

Peptide or peptide-related · Peptide or peptide derivative

Detailed molecular class: Experimental wound peptide

Supplied sequence or chemical reference

See identity note; no supplier sequence accepted as verification.

Mechanism

Functional peptide investigated in wound repair.

Evidence and critical reading

Reported scientific and empirical uses

Recovery and connective tissue · Skin, hair and cosmetics

Functional peptide investigated topically for limb ulcers.

Human evidence

Twelve-person randomized study gave preliminary wound-size signals, insufficient for broad efficacy claims.

Preclinical evidence

Discovery work supports research, not an established treatment.

Critical reading and limitations

The initial trial included only twelve people across four groups; the signal needs confirmation and establishes no systemic effect.

Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.

Source-specific regimens

Descriptive source observations, not individual recommendations.

Regulatory product labeling

No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.

Human-study exposure

No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.

Empirical handbook

No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.

Regulation and safety

Jurisdiction-specific regulatory context

Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.

Adverse effects and unknowns

Very small trial cannot characterize uncommon harms or interactions.

Lack of causal attribution in a few events does not estimate rare harms or long-term safety.

Contraindications

See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.

A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.

Interactions

Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.

Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.

Studies and trials

Selected studies

PMID29449960 · Randomized controlled trial

Skin ulcers; four groups.

Topical, 28 days.

Preliminary lesion-area signal.

Too small for broad efficacy; does not establish systemic delivery.

n = 12

Trials attributed in the package

No trials are attributed in this record.

Trial registration does not establish efficacy or validate commercial material.

Query candidates; attribution pending

SR-0379 · 0 unfiltered query results, not authenticated trials

Query verification: October 16, 2026

Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.

View trial registry query

Source issues and references

References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.

  1. PMID29449960

    Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial.

    Nakagami H, Sugimoto K, Ishikawa T, Fujimoto T, Yamaoka T, Hayashi M, Kiyohara E, Ando H, Terabe Y, Takami Y, Yamamoto K, Takeya Y, Takemoto M, Koshizaka M, Ebihara T, Nakamura A, Nishikawa M, Yao XJ, Hanaoka H, Katayama I, Yokote K, Rakugi H.

    October 16, 2026

  2. R47

    SR-0379 first-in-patient randomized trial, 2018

A community-based bilingual scientific education initiative for healthcare professionals and the general public across the Americas.Currently self-funded; no current sponsors. Formal governance and legal documentation pending.info@peptideamericas.org · Planned contact address — not active yet; please do not send messages.